Furthermore, the absence of PTEN loss may contribute to a more immunologically active tumour microenvironment fostering the possibility of exploring immunotherapies, including immune checkpoint inhibitors, potentially in combination with AR-targeted therapies (62, 103). This evidence concerns the gene PTEN and neoplasm.